All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi, and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
There are several treatment options for treatment-naïve patients with chronic lymphocytic leukemia (CLL), with targeted therapy regimens broadly categorized as continuous or fixed-duration. Among the fixed-duration treatment strategies, the combination of a Bruton’s tyrosine kinase inhibitor (BTKi) with a B-cell lymphoma 2 inhibitor (BCL-2i) has demonstrated efficacy in this patient population.
The Lymphoma Hub spoke with Francesc Bosch and Susan O’Brien to gain their expert insights on the factors influencing BTKi + BCL-2i treatment selection for patients with CLL and the latest clinical data from the CAPTIVATE trial. We also summarize results from the FLAIR trial, which assessed measurable residual disease (MRD)-guided ibrutinib + venetoclax in treatment-naïve patients with CLL.
The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence BTKi + BCL-2i treatment selection for patients with chronic lymphocytic leukemia (CLL)?
The Lymphoma Hub was pleased to speak to Susan O’Brien, Chao Family Comprehensive Cancer Center, University of California, Irvine, US. We asked, What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with chronic lymphocytic leukemia (CLL)?
Several updates from the phase III FLAIR trial of measurable residual disease (MRD)-guided ibrutinib + venetoclax vs ibrutinib monotherapy or fludarabine + cyclophosphamide + rituximab (FCR) in previously untreated patients with chronic lymphocytic leukemia (CLL), were presented by Hillmen, Evans, and Dalal during the 67th ASH Annual Meeting and Exposition 2025.
This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
